Histological assessment of reversal of liver fibrosis and cirrhosis

Zheng YongJian; Wang Yan

doi:10.3969/j.issn.1001-5256.2019.04.002

Volume 35 Issue 4

Apr. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(4): 709-713

PDF( 2001 KB)

Histological assessment of reversal of liver fibrosis and cirrhosis

DOI: 10.3969/j.issn.1001-5256.2019.04.002

State Key Laboratory of Organ Failure Research, Guangdong Provincial Research Center for Liver Fibrosis, Institute of Hepatology, Southern Medical University, Central Laboratory of Southern Medical University, Southern Medical University

Research funding:

Received Date: 2019-01-02
Published Date: 2019-04-20

Abstract

Abstract

Liver fibrogenesis is a common pathway of pathological progression of chronic liver injuries. The diagnosis of liver fibrosis provides an important basis for treatment decision-making and prognostic evaluation of chronic liver diseases. With the rapid development of therapeutics, many new clinical issues have emerged, which requires new techniques for the diagnosis of liver fibrosis. At present, histological assessment remains the most reliable method for a definite diagnosis of liver fibrosis and cirrhosis. With reference to related clinical articles and data, this article analyzes the clinical value and research directions of histological assessment in chronic liver disease management and diagnosis of liver fibrosis/cirrhosis and its reversal.
- liver cirrhosis,
- hepatitis, chronic,
- fatty liver,
- histology

FullText(HTML)

References(48)

References

[1]BEDOSSA P. Reversibility of hepatitis B virus cirrhosis after therapy:Who and why?[J]. Liver Int, 2015, 35 (Suppl 1) :78-81.

[2]POYNARD T, BEDOSSA P, OPOLON P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups[J].Lancet, 1997, 349 (9055) :825-832.

[3]POYNARD T, MOUSSALLI J, MUNTEANU M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C[J]. J Hepatol, 2013, 59 (4) :675-683.

[4]LIU Z, WEI X, CHEN T, et al. Characterization of fibrosis changes in chronic hepatitis C patients after virological cure:A systematic review with meta-analysis[J]. J Gastroenterol Hepatol, 2017, 32 (3) :548-557.

[5]HOEFS JC, SHIFFMAN ML, GOODMAN ZD, et al. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C:Results from the HALT-C Trial[J]. Gastroenterology, 2011, 141 (3) :900-908.

[6]Sh ILI S, GIOVANNA S, FOUCHER J, et al. Post-treatment liver stiffness measurement is not useful to predict hepatocellular carcinoma in HCV patients who achieve SVR[J]. J Hepatol, 2018, 68:s14.

[7]KANWAL F, KRAMER J, ASCH SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents[J]. Gastroenterology, 2017, 153 (4) :996-1005.

[8]PARK JW, CHEN M, COLOMBO M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death:The BRIDGE study[J]. Liver Int, 2015, 35 (9) :2155-2166.

[9]PAPATHEODORIDIS GV, DALEKOS G, YURDAYDIN C, et al.Prediction and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B (CHB) patients of the PAGE-B cohort[J]. Hepatology, 2018, 68:11A-12A.

[10]BROUWER WP, van der MEER AJP, BOONSTRA A, et al.Prediction of long-term clinical outcome in a diverse chronic hepatitis B population:Role of the PAGE-B score[J]. J Viral Hepat, 2017, 24 (11) :1023-1031.

[11]GEORGE J, ANSTEE Q, RATZIU V, et al. NAFLD:The evolving landscape[J]. J Hepatol, 2018, 68 (2) :227-229.

[12]ADAMS LA, SANDERSON S, LINDOR KD, et al. The histological course of nonalcoholic fatty liver disease:A longitudinal study of 103 patients with sequential liver biopsies[J]. J Hepatol, 2005, 42 (1) :132-138.

[13]WONG VW, WONG GL, CHOI PC, et al. Disease progression of non-alcoholic fatty liver disease:A prospective study with paired liver biopsies at 3 years[J]. Gut, 2010, 59 (7) :969-974.

[14]McPHERSON S, HARDY T, HENDERSON E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies:Implications for prognosis and clinical management[J]. J Hepatol, 2015, 62 (5) :1148-1155.

[15]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67 (1) :328-357.

[16]BRUNT EM, KLEINER DE, WILSON LA, et al. Improvements in histologic features and diagnosis associated with improvement in fibrosis in NASH:Results from the NASH clinical research network treatment trials[J]. Hepatology, 2018.[Epub ahead of print]

[17]ANGULO P, KLEINER DE, DAM-LARSEN S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2015, 149 (2) :389-397.

[18]YOUNOSSI ZM, STEPANOVA M, RAFIQ N, et al. Pathologic criteria for nonalcoholic steatohepatitis:Interprotocol agreement and ability to predict liver-related mortality[J]. Hepatology, 2011, 53 (6) :1874-1882.

[19]BRUNT EM, BELT P, WILSON L, et al. Progression to bridging fibrosis in non-alcoholic fatty liver disease over 4 years in the NASH CRN[J]. Hepatology, 2013.[Epub ahead of print]

[20]COLLABORATORS GBDA. Alcohol use and burden for 195countries and territories, 1990-2016:A systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2018, 392 (10152) :1015-1035.

[21]MATHURIN P, BEUZIN F, LOUVET A, et al. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features[J]. Aliment Pharmacol Ther, 2007, 25 (9) :1047-1054.

[22]SINGAL AK, BATALLER R, AHN J, et al. ACG clinical guideline:Alcoholic liver disease[J]. Am J Gastroenterol, 2018, 113 (2) :175-194.

[23]CRABB DW, BATALLER R, CHALASANI NP, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis:Recommendation from the NIAAA alcoholic hepatitis consortia[J]. Gastroenterology, 2016, 150 (4) :785-790.

[24]BATALLER R, GAO B. Liver fibrosis in alcoholic liver disease[J]. Semin Liver Dis, 2015, 35 (2) :146-156.

[25]SZABO G, KAMATH PS, SHAH VH, et al. Alcohol-related liver disease:Areas of consensus, unmet needs and opportunities for further study[J]. Hepatology, 2019.[Epub ahead of print]

[26]TAYLOR LE, SWAN T, MAYER KH. HIV coinfection with hepatitis C virus:Evolving epidemiology and treatment paradigms[J]. Clin Infect Dis, 2012, 55 (Suppl 1) :s33-s42.

[27]RAMESH S, SANYAL AJ. Hepatitis C and nonalcoholic fatty liver disease[J]. Semin Liver Dis, 2004, 24 (4) :399-413.

[28]BEDOSSA P, MOUCARI R, CHELBI E, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C:A prospective study[J]. Hepatology, 2007, 46 (2) :380-387.

[29]KNODELL RG, ISHAK KG, BLACK WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J]. Hepatology, 1981, 1 (5) :431-435.

[30]ISHAK K, BAPTISTA A, BIANCHI L, et al. Histological grading and staging of chronic hepatitis[J]. J Hepatol, 1995, 22 (6) :696-699.

[31]BATTS KP, LUDWIG J. Chronic hepatitis. An update on terminology and reporting[J]. Am J Surg Pathol, 1995, 19 (12) :1409-1417.

[32]BEDOSSA P, POYNARD T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group[J]. Hepatology, 1996, 24 (2) :289-293.

[33]KLEINER DE, BRUNT EM, van NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41 (6) :1313-1321.

[34]BEDOSSA P, CONSORTIUM FP. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J]. Hepatology, 2014, 60 (2) :565-575.

[35]WANLESS IR, SWEENEY G, DHILLON AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia[J]. Blood, 2002, 100 (5) :1566-1569.

[36]KUMAR M, SAKHUJA P, KUMAR A, et al. Histological subclassification of cirrhosis based on histological-haemodynamic correlation[J]. Aliment Pharmacol Ther, 2008, 27 (9) :771-779.

[37]NAGULA S, JAIN D, GROSZMANN RJ, et al. Histologicalhemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis[J]. J Hepatol, 2006, 44 (1) :111-117.

[38]JIMENEZ W, PARES A, CABALLERIA J, et al. Measurement of fibrosis in needle liver biopsies:Evaluation of a colorimetric method[J]. Hepatology, 1985, 5 (5) :815-818.

[39]O'BRIEN MJ, KEATING NM, ELDERINY S, et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C[J]. Am J Clin Pathol, 2000, 114 (5) :712-718.

[40]WANG Y, HOU JL. Fibrosis assessment:Impact on current management of chronic liver disease and application of quantitative invasive tools[J]. Hepatol Int, 2016, 10 (3) :448-461.

[41]ZIPFEL WR, WILLIAMS RM, WEBB WW. Nonlinear magic:Imultiphoton microscopy in the biosciences[J]. Nat Biotechnol, 2003, 21 (11) :1369-1377.

[42]PELLER J, FARAHI F, TRAMMELL SR. Hyperspectral imaging system based on a single-pixel camera design for detecting differences in tissue properties[J]. Appl Opt, 2018, 57 (27) :7651-7658.

[43]XU S, WANG Y, TAI DC, et al. qFibrosis:A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J]. J Hepatol, 2014, 61 (2) :260-269.

[44]WANG Y, VINCENT R, YANG J, et al. Dual-photon microscopy-based quantitation of fibrosis-related parameters (qFP) to model disease progression in steatohepatitis[J]. Hepatology, 2017, 65 (6) :1891-1903.

[45]WANG Y, HUANG W, LI R, et al. Systematic quantification of histological patterns shows accuracy in reflecting cirrhotic remodeling[J]. J Gastroenterol Hepatol, 2017, 32 (9) :1631-1639.

[46]WANG Y, LIANG X, YANG J, et al. Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B[J]. J Viral Hepat, 2018, 25 (5) :598-607.

[47]BEDOSSA P, GARCIA-TSAO G, JAIN D. Cirrhosis regression and subclassification[J]. Surg Pathol Clin, 2013, 6 (2) :295-309.

[48] SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65 (5) :1438-1450.

Relative Articles

[1]	Daqing LIU, Yan HUANG, Jianhe GAN. Value of serum creatinine-to-cystatin C ratio in assessing the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2024, 40(2): 264-270. doi: 10.12449/JCH240208
[2]	Wenling LUO, Yu ZENG, Xuemei ZHANG, Yunjian SHENG. Influence of metabolism-related factors on the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(10): 1985-1991. doi: 10.12449/JCH241010
[3]	Xiaohua LIU, Shujuan YANG, Yushan LIU, Juan LI, Qiao ZHANG, Yamin WANG, Taotao YAN, Yuan YANG, Yingren ZHAO, Yingli HE. Value of peripheral blood lymphocyte count in evaluating the short－term prognosis of patients with acute－on－chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(10): 2383-2389. doi: 10.3969/j.issn.1001-5256.2023.10.016
[4]	Yan WANG, Ying XU, Wei SUN, Li CHEN, Jianhe GAN, Jing GU. Value of interleukin-6 combined with Model for End-Stage Liver Disease score in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(8): 1774-1779. doi: 10.3969/j.issn.1001-5256.2022.08.011
[5]	Shaoyu DONG, Changyu SUN, Fangfang QIAO, Xiao LIU, Jianying ZHANG. Value of age and D-dimer combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(11): 2478-2482. doi: 10.3969/j.issn.1001-5256.2022.11.008
[6]	Tingting DENG, Li LI, Ying GUAN, Xueyan LUO, Kun QIN, Min LIU. Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(10): 2346-2351. doi: 10.3969/j.issn.1001-5256.2022.10.028
[7]	Chenrui LIU, Yaping LI, Sen LUO, Dandan FENG, Fengping WU, Song ZHAI, Shuangsuo DANG. Influencing factors for the short-term prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(1): 56-62. doi: 10.3969/j.issn.1001-5256.2021.01.012
[8]	Dongqing ZHANG, Ruidan ZHENG, Minghua LIN, Wenjun WU, Shenglong LIN, Xiangmei WANG, Huaxi MA, Qin LI, Hanhui YE, Haibing GAO. Influencing factors for the 90-day prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2021.10.011
[9]	Xinyi GAO, Li CHEN, Jianhe GAN. Value of Model for End-Stage Liver Disease score combined with platelet-to-white blood cell ratio in predicting the prognosis of patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(5): 1070-1074. doi: 10.3969/j.issn.1001-5256.2021.05.019
[10]	Yang ShuJuan, Tian Zhen, He YingLi, Zhao YingRen, Zhang Jing, Lu: HengYi, Song HongBo. Predisposing factors for acute-on-chronic liver failure and their influence on prognosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 128-131. doi: 10.3969/j.issn.1001-5256.2020.01.028
[11]	Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(1): 123-127. doi: 10.3969/j.issn.1001-5256.2020.01.027
[12]	Li Chen, Tan JunYuan, Xu Xiang. Development and prognosis of acute-on-chronic liver failure in patients with acute deterioration of hepatitis B virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1960-1965. doi: 10.3969/j.issn.1001-5256.2020.09.010
[13]	Tong JingJing, Mu XiuYing, Xu Xiang, Chen Jing, Zhai XingRan, Wang Yu, Su HaiBin, Liu XiaoYan, Hu JinHua. Association between blood ammonia and 90-day prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1304-1307. doi: 10.3969/j.issn.1001-5256.2019.06.024
[14]	Wang JiaXin, Cheng Na, Xiang TianXin, Li ShuYue, Xiao JinPing, Wu XiaoPing. Establishment and evaluation of short-term prognostic model for hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2019.06.023
[15]	Wang Wei, Zhao RongRong, Yang XiaoFei, Huang ZhangXing, Lian JianQi, Wang JiuPing, Zhang Ye. Influence of Notch signaling pathway on interleukin-22 secreted by CD4~+T cells in patients with hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1315-1318. doi: 10.3969/j.issn.1001-5256.2016.07.020
[16]	Li Long, Wu ZhangHui, Wei Jia. Research progress in association between interleukin 28B gene polymorphism and hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1916-1920. doi: 10.3969/j.issn.1001-5256.2015.11.040
[17]	Lu Ying. Correlation of serum interleukin-33 with HBV DNA load and ALT level in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1853-1856. doi: 10.3969/j.issn.1001-5256.2015.11.020
[18]	Tan GuoLei, Sun Mei, Wang JianFang, Wu XuPing. Relationship between IL- 28B polymorphisms and susceptibility to hepatitis C among Han population in Jiangsu Province, China[J]. Journal of Clinical Hepatology, 2014, 30(6): 514-517. doi: 10.3969/j.issn.1001-5256.2014.06.009
[19]	Shi XiaoDong, Jiang Jing, Niu JunQi. Association of interleukin 28B(IL28B) polymorphisms with the outcomes of HCV infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 28-31.
[20]	Zuo WeiZe, Xu ChunMei, Shen LanChao. Changes in serum level of interleukin-32 and interleukin-6 in patients with chronic hepatitis B virus infection and its clinical significance[J]. Journal of Clinical Hepatology, 2011, 27(4): 408-410+413.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	李炎，孙永岑. 专科护士主导的O2O多学科管理在肝硬化代偿期患者中的应用. 临床护理杂志. 2024(05): 39-43 .
2.	郝志明，窦琴，包晓云. 基于PI3K/Akt信号通路探讨肝康片对四氯化碳致肝纤维化大鼠肝功能的保护机制. 现代消化及介入诊疗. 2020(02): 188-192 .
3.	朱豫萌，朱丹燕，张国强. 中西药合用治疗慢性乙型病毒性肝炎疗效观察. 实用中医药杂志. 2019(09): 1101-1103 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2069) PDF downloads(493)

Histological assessment of reversal of liver fibrosis and cirrhosis

DOI: 10.3969/j.issn.1001-5256.2019.04.002